Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) announced the publication of a global study in the Journal of Electrophoresis, assessing the comparability of its iCE3 and Maurice analytical platforms for charge heterogeneity analysis of therapeutic proteins. The study involved 19 sites across the US, Europe, and China, demonstrating excellent comparability with less than 1.02% standard deviation for charge variants and high precision for isoelectric point values. This advancement supports biopharmaceutical companies in transitioning to the Maurice system, enhancing its market presence and credibility in GMP quality control.
Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 9:30 a.m. EDT. Investors can access the live webcast through Bio-Techne's Investor Relations website. The company is a leader in developing high-quality purified proteins, reagents, and diagnostic products, generating approximately $931 million in net sales in fiscal 2021. With a workforce of around 2,700, Bio-Techne plays a vital role in scientific research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) has entered a partnership with Nonagen Bioscience to exclusively manufacture the Oncuria bladder cancer diagnostic panel. Oncuria utilizes xMAP Luminex technology to provide early detection, therapy selection, and monitoring of bladder cancer. The test received FDA Breakthrough Device Designation in September 2021, which facilitates expedited review and collaboration with the FDA. The Oncuria test is expected to be available by Q4 2022, promising improved patient outcomes through enhanced cancer detection capabilities.
Bio-Techne Corporation (NASDAQ: TECH) announced a significant scientific presence at the American Urological Association Conference from May 13-16, 2022, in New Orleans, LA. Exosome Diagnostics will present two posters and conduct six in-booth scientific presentations, including a live symposium with Cal Ripken, Jr. and Dr. Ronald Tutrone. Key presentations include biomarker studies on prostate cancer and kidney transplant rejection. The ExoDx Prostate test plays a crucial role in early detection, supported by Medicare. One in nine American men will face prostate cancer in their lifetime, highlighting the need for awareness.
Bio-Techne Corporation (NASDAQ: TECH) reported strong financial results for Q3 FY2022, with organic revenue growth of 17% to $290.4 million. GAAP EPS was $1.48, up from $1.12 last year, while adjusted EPS rose to $2.14 from $1.80. Key highlights include 16% organic growth in Protein Sciences and 19% in Diagnostics and Genomics. The company also announced a partnership with Thermo Fisher Scientific for the ExoTRU kidney transplant rejection test. Adjusted operating income increased 17% to $114.6 million, maintaining a robust adjusted operating margin of 39.6%.
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for the quarter ending March 31, 2022. This dividend will be payable on May 27, 2022 to shareholders of record as of May 16, 2022. The company reported approximately $931 million in net sales for fiscal 2021 and continues to provide innovative tools for the life sciences industry. Future dividends will be evaluated quarterly by the Board of Directors.
Bio-Techne Corporation (NASDAQ: TECH) will have its President and CEO, Chuck Kummeth, present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 2:40 p.m. PST. Interested parties can access a live webcast via the company’s Investor Relations website.
Bio-Techne is a key player in creating purified proteins and reagent solutions, with products that cater to biomedical researchers and clinical laboratories. In fiscal 2021, Bio-Techne reported approximately $931 million in net sales. The company has around 2,700 employees globally.
Bio-Techne Corporation (NASDAQ: TECH) plans to host a conference call on May 4, 2022, at 8:00 a.m. CDT to discuss its third quarter fiscal 2022 financial results. Interested parties can join via dial-in or webcast, with the details provided in the release. A replay will be available from 11:00 a.m. CDT on May 4 until 11:00 p.m. CDT on June 4. Bio-Techne reported approximately $931 million in net sales for fiscal 2021 and employs around 2,700 staff globally, focusing on high-quality biological products and diagnostic tools.
Bio-Techne Corporation (NASDAQ: TECH) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI), have launched the Simple Plex™ HEK 293 HCP 3G assay for automated impurity testing on the Ella™ platform. This innovative assay enhances viral production workflows by accurately quantifying host cell protein (HCP) impurities in a rapid, 90-minute process. It promises improved consistency and reduced variability compared to traditional methods, leveraging Cygnus's established HCP detection technology. The collaboration aims to support the growing cell and gene therapy market.